Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression

Autor: Maria Furia, Teresa Troiani, Fortunato Ciardiello, A. L. Muddassir, Floriana Morgillo, V. De Falco, Alexey V. Sorokin, Stefania Napolitano, Emilio Francesco Giunta, Valentina Belli, Erika Martinelli, Giulia Martini, Scott Kopetz, Davide Ciardiello, Nunzia Matrone

Publikováno v: Journal of experimental & clinical cancer research (Online) 38 (2019). doi:10.1186/s13046-019-1497-0
info:cnr-pdr/source/autori:Napolitano S.; Matrone N.; Muddassir A.L.; Martini G.; Sorokin A.; De Falco V.; Giunta E.F.; Ciardiello D.; Martinelli E.; Belli V.; Furia M.; Kopetz S.; Morgillo F.; Ciardiello F.; Troiani T./titolo:Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression/doi:10.1186%2Fs13046-019-1497-0/rivista:Journal of experimental & clinical cancer research (Online)/anno:2019/pagina_da:/pagina_a:/intervallo_pagine:/volume:38
Scientia
Recercat. Dipósit de la Recerca de Catalunya
instname
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Journal of Experimental & Clinical Cancer Research, Vol 38, Iss 1, Pp 1-18 (2019)
Journal of Experimental & Clinical Cancer Research : CR

Background Molecular mechanisms driving acquired resistance to anti-EGFR therapies in metastatic colorectal cancer (mCRC) are complex but generally involve the activation of the downstream RAS-RAF-MEK-MAPK pathway. Nevertheless, even if inhibition of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c37e635a06daf36c9b2902636b96a0e
http://www.cnr.it/prodotto/i/418700